EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients

Meng-Yu Ko iD, Yu-Chung Hsu, Hsu-Heng Yen iD, Siou-Ping Huang iD, Pei-Yuan Su iD

Viruses · 2025

DOI: 10.3390/v17020263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Meng-Yu Ko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Yuanlin Christian Hospital, Changhua 510012, Taiwan. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Insulin Resistance, Antiviral Agents, Lipids. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changhua Christian Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis C virus (HCV) eradication is usually associated with dyslipidemia. Most studies in this field have focused on genotype-specific direct-acting antivirals (DAAs), with research on pangenotypic DAAs being limited. This study examined how two pangenotypic DAA regimens, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), affect lipid profiles and insulin resistance after viral eradication in chronic HCV patients. A total of 100 patients (57 with GLE/PIB and 43 with SOF/VEL) treated between September 2020 and January 2022 were included in the retrospective analysis. This study found a significant increase in LDL and TC levels after treatment (p < 0.001), but no significant changes in triglycerides, high-density lipoprotein, HbA1C, or the Homeostatic Model Assessment of Insulin Resistance. According to a logistic regression analysis, higher baseline LDL or TC and lower baseline glucose are predictors of the degree of increase in LDL or TC following a sustained virological response. Both pangenotypic DAA regimens significantly impact lipid profiles, particularly LDL and TC, but not insulin resistance. This study emphasizes the need for more research into the long-term metabolic effects of DAAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicInsulin ResistanceAntiviral AgentsLipidsHumansMaleMiddle AgedFemaleHepacivirusRetrospective StudiesSofosbuvirPyrrolidinesAgedBenzimidazolesHeterocyclic Compounds, 4 or More RingsSustained Virologic ResponseCarbamatesAdultQuinoxalinesSulfonamides

Stichwörter der Autor:innen

HCVlow-density lipoproteinpangenotypic direct-acting antiviraltotal cholesterol

Substanzen

Antiviral AgentsLipidsSofosbuvirPyrrolidinesBenzimidazolesHeterocyclic Compounds, 4 or More RingsCarbamatesQuinoxalinesSulfonamides

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Yuanlin Christian Hospital, Changhua 510012, Taiwan.
  • Division of Gastroenterology and Hepatology, Changhua Christian Hospital, Changhua 500209, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan.

ORCID-Profile: Meng-Yu Ko, Hsu-Heng Yen, Siou-Ping Huang, Pei-Yuan Su

Förderung

  • Changhua Christian Hospital

Zitieren

APA

Ko, M. Y., Hsu, Y. C., Yen, H. H., Huang, S. P., & Su, P. Y. (2025). The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients. Viruses. https://doi.org/10.3390/v17020263

Vancouver

Ko MY, Hsu YC, Yen HH, Huang SP, Su PY. The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients. Viruses. 2025. doi:10.3390/v17020263

BibTeX
@article{Ko2025,
  author = {Ko, Meng-Yu and Hsu, Yu-Chung and Yen, Hsu-Heng and Huang, Siou-Ping and Su, Pei-Yuan},
  title = {The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17020263}
}
Kostenlos starten →